University of Kansas Cancer Center - Lee's Summit

Summary

University of Kansas Cancer Center - Lee's Summit is a medical facility located in Lees Summit, Missouri. This center is recognized for care of Lung Cancer, Breast Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Cancer and other specialties. University of Kansas Cancer Center - Lee's Summit is involved with conducting 188 clinical trials across 510 conditions. There are 44 research doctors associated with this hospital, such as Jun Zhang, Chao H. Huang, Anwaar Saeed, and Gary C. Doolittle.

Top PIs

Clinical Trials running at University of Kansas Cancer Center - Lee's Summit

Prostate Cancer

Lung Cancer

Breast Cancer

Bladder Cancer

Skin Cancer

Breast cancer

Bladder Carcinoma

Pancreatic Cancer

Cancer

Kidney Cancer

Copper PET Imaging

for Prostate Cancer

This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.

Recruiting

2 awards

Phase 3

4 criteria

Lutetium (177Lu) Vipivotide Tetraxetan

for Prostate Cancer

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).

Recruiting

2 awards

Phase 3

6 criteria

AAA817 + ARPI

for Prostate Cancer

The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of standard of care (SOC) (ARPI change or taxane-based chemotherapy or \[177Lu\]Lu-PSMA-617 (AAA617)) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) treated with another ARPI as last treatment and who have not been exposed to a taxane-containing chemotherapy in the mCRPC setting nor have received any prior PSMA-targeting radioligand therapy.

Recruiting

2 awards

Phase 3

7 criteria